Achieve Life Sciences reports Q1 EPS (37c), consensus (37c)

“The Achieve team is fully committed to finalizing the NDA for submission to the FDA next month. This pivotal milestone is the culmination of our team’s tireless efforts. It marks a critical inflection point as we move towards delivering the first new FDA-approved treatment for smoking cessation in nearly 20 years,” said Rick Stewart, Chief Executive Officer of Achieve. “Cytisinicline has the potential to have a significant benefit on U.S. public health with patients and their healthcare providers needing new options to improve cessation outcomes.”